Abstract：Objective: To explore the relationship between vitamin D levels and the survival status of patients with ovarian cancer. Method: Total 168 patients with ovarian cancer were included during August 2009 to January 2011, then 5 years follow up was conducted, Log rank test and variance analysis were used to compare the progression free survival (rate), 5-year overall survival (rate), and Karnofsky score among patients with different serum 25(OH)D levels. Results: The median progression-free survival and 5-year progression-free survival were not significantly difference among patients with different serum 25(OH)D levels (χ2=2.298, log-rank P=0.513); the median overall survival and 5-year overall survival were significantly difference among patients with different serum 25(OH)D levels (χ2=12.342, log-rank P=0.006), and patients with serum levels of 25.0~49.9 nmoL/L had longest median overall survival, while 50.0~74.9 nmoL/L had highest overall survival rate; Karnofsky scores was also no significantly difference among patients with different serum 25(OH)D levels (P>0.05). Conclusion: The vitamin D levels are associated with the 5 year total survival rate in patients with ovarian cancer, and the survival status of 25.0~74.9 nmoL/L in serum 25 (OH) D was better.
伍雪梅, 蒋红微, 李彬, 彭小凤. 维生素D水平与卵巢癌患者生存状态的关系研究[J]. 河北医学, 2018, 24(4): 667-670.
WU Xuemei, et al. The Relationship between Vitamin D Levels and the Survival Status of Patients with Ovarian Cancer. HeBei Med, 2018, 24(4): 667-670.
[1] 祁晓平,黎介寿.维生素D作为开环甾体激素的研究进展[J].医学研究生学报,2013,26(7):748~750. [2] 李水军,王思合,周建烈,等.维生素D代谢及25-羟基维生素D测定方法研究进展[J].国际检验医学杂志,2012,33(24):3028~3030. [3] Polterauer S, Vergote I, Concin N, et al. Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data[J]. International Journal of Gynecological Cancer, 2012, 22(3): 380~385. [4] Webb P M, de Fazio A, Protani M M, et al. Circulating 25-hydroxyvitamin D and survival in women with ovarian cancer[J]. The American journal of clinical nutrition, 2015: ajcn102681. [5] Johnson M J, Bland J M, Davidson P M, et al. The relationship between two performance scales: New York Heart Association classification and Karnofsky performance status scale[J]. Journal of pain and symptom management, 2014, 47(3): 652~658. [6] 曹雨娜,张虹.维生素D抗肿瘤作用的研究进展[J].中国临床药学杂志,2014,23(2):129~132. [7] 郑敏,刘强.维生素D及维生素D受体的研究进展[J].医学综述,2013,11(19):3965~3967. [8] Toriola A T, Surcel H M, Agborsangaya C, et al. Serum 25-hydroxyvitamin D and the risk of ovarian cancer[J]. European Journal of Cancer, 2010, 46(2): 364~369. [9] Zheng W, Danforth K N, Tworoger S S, et al. Circulating 25-Hydroxyvitamin D and Risk of Epithelial Ovarian Cancer Cohort Consortium Vitamin D Pooling Project of Rarer Cancers[J]. American journal of epidemiology, 2010, 172(1): 70~80. [10] Weinstein S J, Mondul A, Albanes D. Association between pre-diagnostic circulating 25-hydroxyvitamin D and cancer survival[J]. 2016. [11] LEFKOWITZ E S, Garland C F. Sunlight, vitamin D, and ovarian cancer mortality rates in US women[J]. International Journal of Epidemiology, 1994, 23(6): 1133~1136. [12] Kim Y, Je Y. Vitamin D intake, blood 25 (OH) D levels, and breast cancer risk or mortality: a meta-analysis[J]. British journal of cancer, 2014, 110(11): 2772~2784. [13] Javadi S, Ganeshan D M, Qayyum A, et al. Ovarian cancer, the revised FIGO staging system, and the role of Imaging[J]. American Journal of Roentgenology, 2016, 206(6): 1351~1360. [14] 崔伟, 张静,文璞.卵巢癌患者血清25-羟基维生素D,维生素D结合蛋白与Treg细胞及临床病理特征间的关联研究[J].医学理论与实践,2017,30(4):487~488.
2018, Vol. 24 
冀公网安备13080202000677号